CClinicalTrials.gg
CompletedNCT03308968FOCUSUpdated Nov 9, 2021Results posted

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

A Phase 3 interventional study of Fremanezumab and Placebo in Migraine Prophylaxis, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 113 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
838
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments.

Approximately equal numbers of participants from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1 placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all participants continue into an open-label extension of 3 months (up to Week 24) during which everyone is administered sc injections of fremanezumab.

02

Conditions studied

  • Migraine Prophylaxis

Browse trials for

03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The participant has a diagnosis of migraine with onset at ≤50 years of age.
  • Body weight ≥45 kilograms.
  • The participant has a history of migraine for ≥12 months prior to screening.
  • Women of childbearing potential (WOCBP) whose male partners are potentially fertile (that is; no vasectomy) must use highly effective birth control methods for the duration of the study and the follow-up period and for 6.0 months after discontinuation of investigational medicinal product (IMP)
  • Men must be sterile, or if they are potentially fertile/reproductively competent (not surgically [that is; vasectomy] or congenitally sterile) and their female partners are of childbearing potential, must use, together with their female partners, acceptable birth control methods for the duration of the study and for 6.0 months after discontinuation of the investigational medicinal product (IMP).

    • Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • At the time of screening visit, participant is receiving any preventive migraine medications, regardless of the medical indication for more than 5 days and expects to continue with these medications.
  • Participant has received onabotulinumtoxinA for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 3 months before screening visit.
  • The participant has used an intervention/device (for example; scheduled nerve blocks and transcranial magnetic stimulation) for migraine during the 2 months prior to screening.
  • The participant uses triptans/ergots as preventive therapies for migraine.
  • Participant uses non-steroidal anti-inflammatory drugs (NSAIDs) as preventive therapy for migraine on nearly daily basis for other indications. Note: Low dose aspirin (for example; 81 mg) used for cardiovascular disease prevention is allowed.

    • Additional criteria apply, please contact the investigator for more information.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
838 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.

    Drug: Fremanezumab · Drug: Placebo

  • Experimental
    Fremanezumab Quarterly

    DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.

    Drug: Fremanezumab · Drug: Placebo

  • Experimental
    Fremanezumab Monthly

    DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.

    Drug: Fremanezumab · Drug: Placebo

Interventions

  • DrugFremanezumab

    Fremanezumab will be administered per dose and schedule specified in the arm.

    Also known as: TEV-48125

  • DrugPlacebo

    Placebo matching to fremanezumab will be administered per schedule specified in the arm.

05

What researchers measure

Primary outcomes

  1. DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab

    A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28. Change was calculated as post-baseline value - baseline value.

    Time frame: Baseline (Day -28 to Day -1), up to Week 12

Secondary outcomes

  1. DB Period: Percentage of Participants Reaching at Least 50 Percent (%) Reduction From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab

    A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28.

    Time frame: Baseline (Day -28 to Day-1), up to Week 12

  2. DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Period After the First Dose of Fremanezumab

    A headache day of at least moderate severity was defined as a calendar day (00:00 to 23:59) demonstrating at least 4 consecutive hours of headache of at least moderate severity or; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific acute medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects and baseline number of headache days of at least moderate severity and years since onset of migraine as covariates.

    Time frame: Baseline (Day -28 to Day -1), up to Week 12

  3. DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab

    A migraine day was defined as when at least 1 of following occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day demonstrating a headache of any duration that was treated with migraine-specific medications. Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of migraine days and years since onset of migraines as covariates.

    Time frame: Baseline (Day -28 to Day -1), up to Week 4

  4. DB Period: Percentage of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab

    A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28.

    Time frame: Baseline (Day -28 to Day-1), up to Week 4

  5. DB Period: Change From Baseline in Monthly Average Number of Days of Use of Any Acute Headache Medications During the 12-Week Period After the First Dose of Fremanezumab

    Baseline data and the mean change from baseline in the monthly average number of days of use of any acute headache medications during the 12-week period after administration of the first dose of study drug (based on Week 0 to 12 data) is reported. Least Squares (LS) mean calculated using analysis of covariance (ANCOVA) model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of migraine days and years since onset of migraines as covariates.

    Time frame: Baseline (Day -28 to Day -1), up to Week 12

  6. DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period After the First Dose of Fremanezumab

    A headache day of at least moderate severity was defined as a calendar day (00:00 to 23:59) demonstrating at least 4 consecutive hours of headache of at least moderate severity or; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific acute medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of headache days of at least moderate severity and years since onset of migraines as covariates.

    Time frame: Baseline (Day -28 to Day -1), up to Week 4

  7. DB Period: Number of Participants With Adverse Events (AEs) and Who Did Not Complete the Study Due to AEs

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline (Day 0) up to Week 12

  8. OL Period: Number of Participants With AEs and Who Did Not Complete the Study Due to AEs

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  9. DB Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results

    Criteria for potentially clinically significant abnormal serum chemistry values included: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH) (units/liter \[U/L\]): greater than or equal to (≥) 3\*upper limit of normal (ULN); Blood Urea Nitrogen (BUN): ≥10.71 millimoles/liter (mmol/L); creatinine: ≥177 micromoles/liter (µmol/L); bilirubin (total): ≥34.2 µmol/L; and uric acid: ≥625 µmol/L (men), and ≥506 µmol/L (women). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  10. OL Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results

    Criteria for potentially clinically significant abnormal serum chemistry values included: ALT, AST, ALP, GGT, and LDH (U/L): ≥3\*ULN; BUN: ≥10.71 mmol/L; creatinine: ≥177 µmol/L; bilirubin (total): ≥34.2 µmol/L; and uric acid: ≥625 µmol/L (men), and ≥506 µmol/L (women). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  11. DB Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results

    Criteria for potentially clinically significant abnormal hematology values included: hemoglobin: less than (\<) 115 grams/liter (g/L) (in men) or less than or equal to (≤) 95 g/L (in women), hematocrit: \<0.37 L/L (in men) or \<0.32 L/L (in women), leukocytes: ≥20\*10\^9/L or ≤3\*10\^9/L, eosinophils: \>=10%, platelets: ≥700\*10\^9/L or ≤75\*10\^9/L, and absolute neutrophil count (ANC): ≤1\*10\^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  12. OL Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results

    Criteria for potentially clinically significant abnormal hematology values included: hemoglobin: \<115 g/L (in men) or ≤95 g/L (in women), hematocrit: \<0.37 L/L (in men) or \<0.32 L/L (in women), leukocytes: ≥20\*10\^9/L or ≤3\*10\^9/L, eosinophils: \>=10%, platelets: ≥700\*10\^9/L or ≤75\*10\^9/L, and ANC: ≤1\*10\^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  13. DB Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results

    Criteria for potentially clinically significant abnormal coagulation values included: prothrombin international normalized ratio (INR): greater than (\>) 1.5. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  14. OL Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results

    Criteria for potentially clinically significant abnormal coagulation values included: prothrombin INR: \>1.5. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  15. DB Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results

    Criteria for potentially clinically significant abnormal urinalysis values included: urine glucose (milligrams/deciliter \[mg/dL\]): ≥2 unit increase from baseline, ketones (mg/dL): ≥2 unit increase from baseline, urine total protein (mg/dL): ≥2 unit increase from baseline, and haemoglobin ≥2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  16. OL Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results

    Criteria for potentially clinically significant abnormal urinalysis values included: urine glucose (mg/dL): ≥2 unit increase from baseline, ketones (mg/dL): ≥2 unit increase from baseline, urine total protein (mg/dL): ≥2 unit increase from baseline, and haemoglobin ≥2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  17. DB Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values

    Criteria for potentially clinically significant abnormal vital signs values included: pulse rate: ≤50 beats/minute (bpm) and decrease of ≥15 bpm, or ≥120 bpm and increase of ≥15 bpm; systolic blood pressure: ≤90 millimeters of mercury (mmHg) and decrease of ≥20 mmHg, or ≥180 mmHg and increase of ≥20 mmHg; diastolic blood pressure: ≤50 mmHg and decrease of ≥15 mmHg or ≥105 mmHg and increase of ≥15 mmHg; respiratory rate: \<10 breaths/minute; and body temperature ≥38.3 degrees celsius and change of ≥1.1 degrees celsius. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  18. OL Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values

    Criteria for potentially clinically significant abnormal vital signs values included: pulse rate: ≤50 bpm and decrease of ≥15 bpm, or ≥120 bpm and increase of ≥15 bpm; systolic blood pressure: ≤90 mmHg and decrease of ≥20 mmHg, or ≥180 mmHg and increase of ≥20 mmHg; diastolic blood pressure: ≤50 mmHg and decrease of ≥15 mmHg or ≥105 mmHg and increase of ≥15 mmHg; respiratory rate: \<10 breaths/minute; and body temperature ≥38.3 degrees celsius and change of ≥1.1 degrees celsius. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  19. DB Period: Number of Participants With Shift From Baseline to Week 12 in Electrocardiogram (ECG) Parameters

    ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - Week 12 value. Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline, Week 12

  20. OL Period: Number of Participants With Shift From Baseline to Week 24 in ECG Parameters

    ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - Week 24 value. Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline, Week 24

  21. DB Period: Number of Participants Who Received Concomitant Medications for Adverse Events

    Concomitant medications included: agents acting on the renin-angiotensin system, all other therapeutic products (for example: homeopathic preparation), allergens, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antibiotics and chemotherapeutics for dermatological use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetic, antiepileptics, antifungals for dermatologiocal use, antigout preparations, antihemorrhagics, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatic products, antimycotics for systemic use, antipruritics, antipsoriatics, antivirals for systemic use, beta blocking agents, blood substitutes and perfusion solutions, cardiac therapy, corticosteroids, cough and cold preparations, diagnostic radiopharmaceuticals, diuretics, thyroid therapy, urologicals, vaccines, psycoleptics, psycoanaleptics, ophthalmologicals, muscle relaxants, drugs used in diabetes etc.

    Time frame: Baseline up to Week 12

  22. OL Period: Number of Participants Who Received Concomitant Medications for Adverse Events

    Concomitant medications included: agents acting on the renin-angiotensin system, all other therapeutic products (for example: homeopathic preparation), allergens, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antibiotics and chemotherapeutics for dermatological use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetic, antiepileptics, antifungals for dermatologiocal use, antigout preparations, antihemorrhagics, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatic products, antimycotics for systemic use, antipruritics, antipsoriatics, antivirals for systemic use, beta blocking agents, blood substitutes and perfusion solutions, cardiac therapy, corticosteroids, cough and cold preparations, diagnostic radiopharmaceuticals, diuretics, thyroid therapy, urologicals, vaccines, psycoleptics, psycoanaleptics, ophthalmologicals, muscle relaxants, drugs used in diabetes etc.

    Time frame: Week 12 up to Week 24

06

Results

Posted Oct 9, 2019

Participant flow

Double-Blind Period (12 Weeks)
Participant flow — Double-Blind Period (12 Weeks)
MilestonePlaceboFremanezumab QuarterlyFremanezumab Monthly
Started279276283
Db safety analysis set277276285
Db modified itt (mitt) analysis set278276283
Completed264271272
Not completed15511
Withdrew: Adverse event314
Withdrew: Withdrawal by subject223
Withdrew: Protocol violation602
Withdrew: Non-compliance to study procedures110
Withdrew: Lost to follow-up100
Withdrew: Lack of efficacy110
Withdrew: Other than specified102
Open-Label Period (12 Weeks)
Participant flow — Open-Label Period (12 Weeks)
MilestonePlaceboFremanezumab QuarterlyFremanezumab Monthly
Started264271272
Ol mitt analysis set263271272
Completed253259260
Not completed111212
Withdrew: Other than specified121
Withdrew: Adverse event411
Withdrew: Withdrawal by subject557
Withdrew: Protocol violation011
Withdrew: Non-compliance to study procedures001
Withdrew: Lost to follow-up011
Withdrew: Lack of efficacy120

Outcome measures

PrimaryDB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab

A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28. Change was calculated as post-baseline value - baseline value.

Time frame:
Baseline (Day -28 to Day -1), up to Week 12
Reported as:
Least squares mean · days/month
DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab
days/monthPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab-0.6 ± 0.34-3.7 ± 0.34-4.1 ± 0.34
Statistical analysis
  • Placebo vs Fremanezumab Quarterly · ANCOVA · p = <0.0001 · Least square (ls) mean difference: -3.1 · 95% CI -3.84 to -2.42
  • Placebo vs Fremanezumab Monthly · ANCOVA · p = <0.0001 · Ls mean difference: -3.5 · 95% CI -4.19 to -2.78
SecondaryDB Period: Percentage of Participants Reaching at Least 50 Percent (%) Reduction From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab

A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28.

Time frame:
Baseline (Day -28 to Day-1), up to Week 12
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Reaching at Least 50 Percent (%) Reduction From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab
percentage of participantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Percentage of Participants Reaching at Least 50 Percent (%) Reduction From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab93434
SecondaryDB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Period After the First Dose of Fremanezumab

A headache day of at least moderate severity was defined as a calendar day (00:00 to 23:59) demonstrating at least 4 consecutive hours of headache of at least moderate severity or; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific acute medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects and baseline number of headache days of at least moderate severity and years since onset of migraine as covariates.

Time frame:
Baseline (Day -28 to Day -1), up to Week 12
Reported as:
Least squares mean · days/month
DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Period After the First Dose of Fremanezumab
days/monthPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Period After the First Dose of Fremanezumab-0.6 ± 0.33-3.9 ± 0.34-4.2 ± 0.34
SecondaryDB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab

A migraine day was defined as when at least 1 of following occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day demonstrating a headache of any duration that was treated with migraine-specific medications. Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of migraine days and years since onset of migraines as covariates.

Time frame:
Baseline (Day -28 to Day -1), up to Week 4
Reported as:
Least squares mean · days/month
DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab
days/monthPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab-0.6 ± 0.35-4.1 ± 0.35-4.1 ± 0.35
SecondaryDB Period: Percentage of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab

A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)\*28.

Time frame:
Baseline (Day -28 to Day-1), up to Week 4
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab
percentage of participantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Percentage of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab103836
SecondaryDB Period: Change From Baseline in Monthly Average Number of Days of Use of Any Acute Headache Medications During the 12-Week Period After the First Dose of Fremanezumab

Baseline data and the mean change from baseline in the monthly average number of days of use of any acute headache medications during the 12-week period after administration of the first dose of study drug (based on Week 0 to 12 data) is reported. Least Squares (LS) mean calculated using analysis of covariance (ANCOVA) model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of migraine days and years since onset of migraines as covariates.

Time frame:
Baseline (Day -28 to Day -1), up to Week 12
Reported as:
Least squares mean · days/month
DB Period: Change From Baseline in Monthly Average Number of Days of Use of Any Acute Headache Medications During the 12-Week Period After the First Dose of Fremanezumab
days/monthPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Change From Baseline in Monthly Average Number of Days of Use of Any Acute Headache Medications During the 12-Week Period After the First Dose of Fremanezumab-0.6 ± 0.32-3.7 ± 0.32-3.9 ± 0.32
SecondaryDB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period After the First Dose of Fremanezumab

A headache day of at least moderate severity was defined as a calendar day (00:00 to 23:59) demonstrating at least 4 consecutive hours of headache of at least moderate severity or; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific acute medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean calculated using ANCOVA model with treatment, gender, region, special group of treatment failure (yes/no), migraine classification (EM/CM), and treatment\*migraine classification as fixed effects, and baseline number of headache days of at least moderate severity and years since onset of migraines as covariates.

Time frame:
Baseline (Day -28 to Day -1), up to Week 4
Reported as:
Least squares mean · days/month
DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period After the First Dose of Fremanezumab
days/monthPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period After the First Dose of Fremanezumab-0.5 ± 0.34-4.2 ± 0.35-4.5 ± 0.34
SecondaryDB Period: Number of Participants With Adverse Events (AEs) and Who Did Not Complete the Study Due to AEs

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline (Day 0) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Adverse Events (AEs) and Who Did Not Complete the Study Due to AEs
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
Any AEs134151129
AEs leading to withdrawal from study314
SecondaryOL Period: Number of Participants With AEs and Who Did Not Complete the Study Due to AEs

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With AEs and Who Did Not Complete the Study Due to AEs
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
Any AEs137149155
AEs leading to withdrawal from study412
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results

Criteria for potentially clinically significant abnormal serum chemistry values included: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH) (units/liter \[U/L\]): greater than or equal to (≥) 3\*upper limit of normal (ULN); Blood Urea Nitrogen (BUN): ≥10.71 millimoles/liter (mmol/L); creatinine: ≥177 micromoles/liter (µmol/L); bilirubin (total): ≥34.2 µmol/L; and uric acid: ≥625 µmol/L (men), and ≥506 µmol/L (women). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results134
SecondaryOL Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results

Criteria for potentially clinically significant abnormal serum chemistry values included: ALT, AST, ALP, GGT, and LDH (U/L): ≥3\*ULN; BUN: ≥10.71 mmol/L; creatinine: ≥177 µmol/L; bilirubin (total): ≥34.2 µmol/L; and uric acid: ≥625 µmol/L (men), and ≥506 µmol/L (women). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results232
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results

Criteria for potentially clinically significant abnormal hematology values included: hemoglobin: less than (\<) 115 grams/liter (g/L) (in men) or less than or equal to (≤) 95 g/L (in women), hematocrit: \<0.37 L/L (in men) or \<0.32 L/L (in women), leukocytes: ≥20\*10\^9/L or ≤3\*10\^9/L, eosinophils: \>=10%, platelets: ≥700\*10\^9/L or ≤75\*10\^9/L, and absolute neutrophil count (ANC): ≤1\*10\^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results11123
SecondaryOL Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results

Criteria for potentially clinically significant abnormal hematology values included: hemoglobin: \<115 g/L (in men) or ≤95 g/L (in women), hematocrit: \<0.37 L/L (in men) or \<0.32 L/L (in women), leukocytes: ≥20\*10\^9/L or ≤3\*10\^9/L, eosinophils: \>=10%, platelets: ≥700\*10\^9/L or ≤75\*10\^9/L, and ANC: ≤1\*10\^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Hematology Results9115
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results

Criteria for potentially clinically significant abnormal coagulation values included: prothrombin international normalized ratio (INR): greater than (\>) 1.5. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results244
SecondaryOL Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results

Criteria for potentially clinically significant abnormal coagulation values included: prothrombin INR: \>1.5. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Coagulation Laboratory Test Results313
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results

Criteria for potentially clinically significant abnormal urinalysis values included: urine glucose (milligrams/deciliter \[mg/dL\]): ≥2 unit increase from baseline, ketones (mg/dL): ≥2 unit increase from baseline, urine total protein (mg/dL): ≥2 unit increase from baseline, and haemoglobin ≥2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results000
SecondaryOL Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results

Criteria for potentially clinically significant abnormal urinalysis values included: urine glucose (mg/dL): ≥2 unit increase from baseline, ketones (mg/dL): ≥2 unit increase from baseline, urine total protein (mg/dL): ≥2 unit increase from baseline, and haemoglobin ≥2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results000
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values

Criteria for potentially clinically significant abnormal vital signs values included: pulse rate: ≤50 beats/minute (bpm) and decrease of ≥15 bpm, or ≥120 bpm and increase of ≥15 bpm; systolic blood pressure: ≤90 millimeters of mercury (mmHg) and decrease of ≥20 mmHg, or ≥180 mmHg and increase of ≥20 mmHg; diastolic blood pressure: ≤50 mmHg and decrease of ≥15 mmHg or ≥105 mmHg and increase of ≥15 mmHg; respiratory rate: \<10 breaths/minute; and body temperature ≥38.3 degrees celsius and change of ≥1.1 degrees celsius. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values988
SecondaryOL Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values

Criteria for potentially clinically significant abnormal vital signs values included: pulse rate: ≤50 bpm and decrease of ≥15 bpm, or ≥120 bpm and increase of ≥15 bpm; systolic blood pressure: ≤90 mmHg and decrease of ≥20 mmHg, or ≥180 mmHg and increase of ≥20 mmHg; diastolic blood pressure: ≤50 mmHg and decrease of ≥15 mmHg or ≥105 mmHg and increase of ≥15 mmHg; respiratory rate: \<10 breaths/minute; and body temperature ≥38.3 degrees celsius and change of ≥1.1 degrees celsius. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values10148
SecondaryDB Period: Number of Participants With Shift From Baseline to Week 12 in Electrocardiogram (ECG) Parameters

ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - Week 12 value. Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline, Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Shift From Baseline to Week 12 in Electrocardiogram (ECG) Parameters
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
Normal - Normal199218212
Normal - Abnormal NCS211415
Normal - Abnormal CS000
Abnormal NCS - Normal101912
Abnormal NCS - Abnormal NCS282031
Abnormal NCS - Abnormal CS000
Abnormal CS - Normal000
Abnormal CS - Abnormal NCS000
Abnormal CS - Abnormal CS000
SecondaryOL Period: Number of Participants With Shift From Baseline to Week 24 in ECG Parameters

ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - Week 24 value. Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline, Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With Shift From Baseline to Week 24 in ECG Parameters
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
Normal - Normal194215204
Normal - Abnormal NCS15515
Normal - Abnormal CS001
Abnormal NCS - Normal142016
Abnormal NCS - Abnormal NCS241725
Abnormal NCS - Abnormal CS000
Abnormal CS - Normal000
Abnormal CS - Abnormal NCS000
Abnormal CS - Abnormal CS000
SecondaryDB Period: Number of Participants Who Received Concomitant Medications for Adverse Events

Concomitant medications included: agents acting on the renin-angiotensin system, all other therapeutic products (for example: homeopathic preparation), allergens, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antibiotics and chemotherapeutics for dermatological use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetic, antiepileptics, antifungals for dermatologiocal use, antigout preparations, antihemorrhagics, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatic products, antimycotics for systemic use, antipruritics, antipsoriatics, antivirals for systemic use, beta blocking agents, blood substitutes and perfusion solutions, cardiac therapy, corticosteroids, cough and cold preparations, diagnostic radiopharmaceuticals, diuretics, thyroid therapy, urologicals, vaccines, psycoleptics, psycoanaleptics, ophthalmologicals, muscle relaxants, drugs used in diabetes etc.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants Who Received Concomitant Medications for Adverse Events
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
DB Period: Number of Participants Who Received Concomitant Medications for Adverse Events274269280
SecondaryOL Period: Number of Participants Who Received Concomitant Medications for Adverse Events

Concomitant medications included: agents acting on the renin-angiotensin system, all other therapeutic products (for example: homeopathic preparation), allergens, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antibiotics and chemotherapeutics for dermatological use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetic, antiepileptics, antifungals for dermatologiocal use, antigout preparations, antihemorrhagics, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatic products, antimycotics for systemic use, antipruritics, antipsoriatics, antivirals for systemic use, beta blocking agents, blood substitutes and perfusion solutions, cardiac therapy, corticosteroids, cough and cold preparations, diagnostic radiopharmaceuticals, diuretics, thyroid therapy, urologicals, vaccines, psycoleptics, psycoanaleptics, ophthalmologicals, muscle relaxants, drugs used in diabetes etc.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants Who Received Concomitant Medications for Adverse Events
ParticipantsPlaceboFremanezumab QuarterlyFremanezumab Monthly
OL Period: Number of Participants Who Received Concomitant Medications for Adverse Events262266270

Adverse events

Collected over Baseline (Day 0) up to follow-up visit (Week 46). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/277 (0%)13/277 (4.7%)88/277 (31.8%)
Fremanezumab Quarterly0/276 (0%)10/276 (3.6%)90/276 (32.6%)
Fremanezumab Monthly0/285 (0%)11/285 (3.9%)81/285 (28.4%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPlaceboFremanezumab QuarterlyFremanezumab Monthly
NephrolithiasisRenal and urinary disorders0/2770/2762/285
DysmenorrhoeaReproductive system and breast disorders0/2311/2290/240
MenorrhagiaReproductive system and breast disorders0/2311/2290/240
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2310/2290/240
Vulval cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2310/2290/240
MetrorrhagiaReproductive system and breast disorders1/2310/2290/240
EndometriosisReproductive system and breast disorders0/2310/2291/240
MenometrorrhagiaReproductive system and breast disorders0/2310/2291/240
Anal polypGastrointestinal disorders0/2771/2760/285
Gastrooesophageal reflux diseaseGastrointestinal disorders0/2771/2760/285
Most frequent other events
Most frequent other events
EventPlaceboFremanezumab QuarterlyFremanezumab Monthly
NasopharyngitisInfections and infestations32/27730/27625/285
Injection site erythemaGeneral disorders24/27731/27632/285
MigraineNervous system disorders21/27714/27612/285
Injection site indurationGeneral disorders16/27719/27618/285
Upper respiratory tract infectionInfections and infestations10/2778/27616/285
Injection site painGeneral disorders10/27715/27614/285

Baseline characteristics

ITT analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
Mean46.8 ± 11.1045.8 ± 10.9745.9 ± 11.0546.2 ± 11.04
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
Female233229238700
Male464745138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
Hispanic or Latino116724
Not Hispanic or Latino255260264779
Unknown or Not Reported13101235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
American Indian or Alaska Native0011
Asian1034
Native Hawaiian or Other Pacific Islander0000
Black or African American2248
White262262262786
Other1214
Unknown or Not Reported13101235
Number of Migraine Days During the 28 Day Baseline Period
Number of Migraine Days During the 28 Day Baseline Period(days)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
Mean14.3 ± 6.1214.1 ± 5.6114.1 ± 5.5814.2 ± 5.77
Number of Headache Days of at Least Moderate Severity During the 28 Day Baseline Period
Number of Headache Days of at Least Moderate Severity During the 28 Day Baseline Period(days)PlaceboFremanezumab QuarterlyFremanezumab MonthlyTotal
Mean12.8 ± 5.9212.4 ± 5.8412.7 ± 5.8212.6 ± 5.85
07

Study locations

113 sites
  • Teva Investigational Site 14742
    Huntsville, Alabama 35801, United States
  • Teva Investigational Site 14729
    Long Beach, California 90806, United States
  • Teva Investigational Site 14739
    San Diego, California 92103, United States
  • Teva Investigational Site 14843
    Santa Monica, California 90404, United States
  • Teva Investigational Site 14749
    Colorado Springs, Colorado 80918, United States
  • Teva Investigational Site 14758
    Maitland, Florida 32751, United States
  • Teva Investigational Site 14738
    Orlando, Florida 32819, United States
  • Teva Investigational Site 14760
    Decatur, Georgia 30030, United States
  • Teva Investigational Site 14737
    Meridian, Idaho 83642, United States
  • Teva Investigational Site 14730
    Chicago, Illinois 60607, United States
  • Teva Investigational Site 14740
    Evanston, Illinois 60201, United States
  • Teva Investigational Site 14735
    Louisville, Kentucky 40223, United States
  • Teva Investigational Site 14747
    Pikesville, Maryland 21208, United States
  • Teva Investigational Site 14750
    Fall River, Massachusetts 02720, United States
  • Teva Investigational Site 14734
    Watertown, Massachusetts 02472, United States
  • Teva Investigational Site 14731
    Ann Arbor, Michigan 48104, United States
  • Teva Investigational Site 14748
    Plymouth, Minnesota 55441, United States
  • Teva Investigational Site 14746
    Omaha, Nebraska 68114, United States
  • Teva Investigational Site 14754
    Berlin, New Jersey 08009, United States
  • Teva Investigational Site 14752
    Albuquerque, New Mexico 87102, United States
  • Teva Investigational Site 14753
    Amherst, New York 14226, United States
  • Teva Investigational Site 14736
    Greensboro, North Carolina 27405, United States
  • Teva Investigational Site 14741
    Greensboro, North Carolina 27408, United States
  • Teva Investigational Site 14732
    Raleigh, North Carolina 27607, United States
  • Teva Investigational Site 14761
    Lincoln, Rhode Island 02865, United States
  • Teva Investigational Site 14756
    Warwick, Rhode Island 02886, United States
  • Teva Investigational Site 14745
    Memphis, Tennessee 38119, United States
  • Teva Investigational Site 14743
    Nashville, Tennessee 37203, United States
  • Teva Investigational Site 14733
    Austin, Texas 78731, United States
  • Teva Investigational Site 14751
    West Jordan, Utah 84088, United States
  • Teva Investigational Site 37092
    Brugge, 8000, Belgium
  • Teva Investigational Site 37089
    Brussels, 1090, Belgium
  • Teva Investigational Site 37091
    Hasselt, 3500, Belgium
  • Teva Investigational Site 37090
    Liege, 4000, Belgium
  • Teva Investigational Site 54162
    Brno, 602 00, Czechia
  • Teva Investigational Site 54165
    Ostrava-Moravska, 702 00, Czechia
  • Teva Investigational Site 54159
    Ostrava, 70200, Czechia
  • Teva Investigational Site 54158
    Pardubice, 53002, Czechia
  • Teva Investigational Site 54164
    Prague 4, 140 59, Czechia
  • Teva Investigational Site 54163
    Prague, 100 00, Czechia
  • Teva Investigational Site 54160
    Praha 10, 160 00, Czechia
  • Teva Investigational Site 54161
    Praha 3, 130 00, Czechia
  • Teva Investigational Site 54166
    Praha 8, 186 00, Czechia
  • Teva Investigational Site 54157
    Rychnov nad Kneznou, 51601, Czechia
  • Teva Investigational Site 39051
    Aalborg, 9000, Denmark
  • Teva Investigational Site 39049
    Arhus, 8000, Denmark
  • Teva Investigational Site 39052
    Ballerup, 2750, Denmark
  • Teva Investigational Site 39048
    Glostrup, 2600, Denmark
  • Teva Investigational Site 39050
    Vejle, 7100, Denmark
  • Teva Investigational Site 40034
    Helsinki, 00180, Finland
  • Teva Investigational Site 40035
    Helsinki, 00930, Finland
  • Teva Investigational Site 40036
    Oulu, 90100, Finland
  • Teva Investigational Site 40033
    Tampere, FI-33100, Finland
  • Teva Investigational Site 40032
    Turku, 20100, Finland
  • Teva Investigational Site 40037
    Turku, 20520, Finland
  • Teva Investigational Site 35237
    Bron Cedex, 69677, France
  • Teva Investigational Site 35238
    Lille, 59037, France
  • Teva Investigational Site 35235
    Marseille, 13005, France
  • Teva Investigational Site 35240
    Nice, 06000, France
  • Teva Investigational Site 35239
    Strasbourg, 67098, France
  • Teva Investigational Site 35236
    Voiron, 38500, France
  • Teva Investigational Site 32697
    Berlin, 10177, Germany
  • Teva Investigational Site 32690
    Berlin, D-10435, Germany
  • Teva Investigational Site 32694
    Bochum, 44787, Germany
  • Teva Investigational Site 32699
    Essen, 45147, Germany
  • Teva Investigational Site 32692
    Goppingen, 73033, Germany
  • Teva Investigational Site 32691
    Halle, 06120, Germany
  • Teva Investigational Site 32698
    Hamburg, 20251, Germany
  • Teva Investigational Site 32700
    Kiel, 24149, Germany
  • Teva Investigational Site 32695
    Konigstein im Taunus, 61462, Germany
  • Teva Investigational Site 32689
    Muenchen, 81377, Germany
  • Teva Investigational Site 32701
    Rostock, 18147, Germany
  • Teva Investigational Site 32693
    Ulm, 89073, Germany
  • Teva Investigational Site 30199
    Firenze, 50134, Italy
  • Teva Investigational Site 30204
    Roma, 00128, Italy
  • Teva Investigational Site 38126
    Amsterdam, 1078VV, Netherlands
  • Teva Investigational Site 38127
    Blaricum, 1261 AN, Netherlands
  • Teva Investigational Site 38124
    Leiden, 2333 ZA, Netherlands
  • Teva Investigational Site 38125
    Tilburg, 5042 AD, Netherlands
  • Teva Investigational Site 53420
    Krakow, 31-209, Poland
  • Teva Investigational Site 53425
    Krakow, 33-332, Poland
  • Teva Investigational Site 53422
    Lodz, 90-338, Poland
  • Teva Investigational Site 53424
    Lodz, 90-368, Poland
  • Teva Investigational Site 53418
    Lublin, 20-022, Poland
  • Teva Investigational Site 53416
    Poznan, 60-529, Poland
  • Teva Investigational Site 53419
    Szczecin, 70-111, Poland
  • Teva Investigational Site 53417
    Warszawa, 00-909, Poland
  • Teva Investigational Site 53423
    Warszawa, 04-730, Poland
  • Teva Investigational Site 31231
    Barcelona, 08035, Spain
  • Teva Investigational Site 31235
    Madrid, 28223, Spain
  • Teva Investigational Site 31236
    Madrid, 28942, Spain
  • Teva Investigational Site 31226
    Pamplona, 31008, Spain
  • Teva Investigational Site 31229
    Santander, 39008, Spain
  • Teva Investigational Site 31230
    Santiago de Compostela, 15706, Spain
  • Teva Investigational Site 31234
    Sevilla, 41013, Spain
  • Teva Investigational Site 31233
    Valencia, 46010, Spain
  • Teva Investigational Site 31227
    Valencia, 46026, Spain
  • Teva Investigational Site 31225
    Valladolid, 47003, Spain
  • Teva Investigational Site 31228
    Zaragoza, 50009, Spain
  • Teva Investigational Site 42050
    Helsingborg, 252 20, Sweden

Showing the first 100 of 113 sites across 14 countries.

08

References and documents

Publications

  • McAllister P, Cohen JM, Campos VR, Ning X, Janka L, Barash S. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. J Headache Pain. 2022 Aug 29;23(1):112. doi: 10.1186/s10194-022-01438-4. PubMed 36038833 ↗
  • Diener HC, McAllister P, Jurgens TP, Kessler Y, Ning X, Cohen JM, Campos VR, Barash S, Silberstein SD. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. Cephalalgia. 2022 Jul;42(8):769-780. doi: 10.1177/03331024221076485. Epub 2022 Mar 25. PubMed 35331009 ↗
  • Lampl C, Rapoport AM, Cohen JM, Barash S, Ramirez Campos V, Seminerio MJ, Ning X, Silberstein SD. Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction. Eur J Neurol. 2022 Jul;29(7):2129-2137. doi: 10.1111/ene.15328. Epub 2022 Mar 29. PubMed 35302681 ↗
  • MaassenVanDenBrink A, Terwindt GM, Cohen JM, Barash S, Campos VR, Galic M, Ning X, Karppa M. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. J Headache Pain. 2021 Dec 18;22(1):152. doi: 10.1186/s10194-021-01336-1. PubMed 34922436 ↗
  • Nahas SJ, Naegel S, Cohen JM, Ning X, Janka L, Campos VR, Krasenbaum LJ, Holle-Lee D, Kudrow D, Lampl C. Efficacy and safety of fremanezumab in clinical trial participants aged >/=60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain. 2021 Nov 24;22(1):141. doi: 10.1186/s10194-021-01351-2. Erratum In: J Headache Pain. 2022 May 17;23(1):57. doi: 10.1186/s10194-022-01423-x. PubMed 34819017 ↗
  • Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7. PubMed 34246226 ↗
  • Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P. Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response. Cephalalgia. 2021 Sep;41(10):1075-1088. doi: 10.1177/03331024211008401. Epub 2021 May 14. PubMed 33990144 ↗
  • Spierings ELH, Karppa M, Ning X, Cohen JM, Campos VR, Yang R, Reuter U. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial. J Headache Pain. 2021 Apr 16;22(1):26. doi: 10.1186/s10194-021-01232-8. PubMed 33863272 ↗
  • Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019 Sep 21;394(10203):1030-1040. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16. Erratum In: Lancet. 2024 Aug 31;404(10455):e3. doi: 10.1016/S0140-6736(19)32643-1. PubMed 31427046 ↗

Study documents

  • Study protocol · Oct 23, 2017
  • Statistical analysis plan · Nov 13, 2018

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03308968
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2017
Start date
Oct 13, 2017
Primary completion
Oct 2, 2018
Completion
May 29, 2019
Results posted
Oct 9, 2019
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion